RCM
NKGN

Robinson Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Robinson Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,000
Closed -$122K – 281
2023
Q1 		$122K Hold
12,000
– – 0.06% 176
2022
Q4 		$120K Buy
12,000
+2,956
+33% +$29.2K 0.06% 180
2022
Q3 		$88K Buy
+9,044
New +$88.2K 0.07% 207

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Robinson Capital Management's NKGN Position: Q2 2023 in Review

Robinson Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 12,000 shares — an estimated $122K sold.

Robinson Capital Management first reported a position in NKGN in Q3 2022 and held it in 3 quarters. The position peaked at $122K in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Robinson Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Robinson Capital Management sold 12,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $122K.
  • Robinson Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Robinson Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $122K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Robinson Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.